Wegner-Houghton equation and derivative expansion

We study the derivative expansion for the effective action in the framework of the Exact Renormalization Group for a single component scalar theory. By truncating the expansion to the first two terms, the potential $U_k$ and the kinetic coefficient $Z_k$, our analysis suggests that a set of coupled differential equations for these two functions can be established under certain smoothness conditions for the background field and that sharp and smooth cut-off give the same result. In addition we find that, differently from the case of the potential, a further expansion is needed to obtain the differential equation for $Z_k$, according to the relative weight between the kinetic and the potential terms. As a result, two different approximations to the $Z_k$ equation are obtained. Finally a numerical analysis of the coupled equations for $U_k$ and $Z_k$ is performed at the non-gaussian fixed point in $D<4$ dimensions to determine the anomalous dimension of the field.Comment: 15 pages, 3 figure

Nonextensive statistical effects in protoneutron stars

We investigate the bulk properties of protoneutron stars in the framework of a relativistic mean field theory based on nonextensive statistical mechanics, characterized by power-law quantum distributions. We study the relevance of nonextensive statistical effects on the beta-stable equation of state at fixed entropy per baryon, in presence and in absence of trapped neutrinos, for nucleonic and hyperonic matter. We show that nonextensive statistical effects could play a crucial role in the structure and in the evolution of the protoneutron stars also for small deviations from the standard Boltzmann-Gibbs statistics.Comment: 9 pages, 7 figure

Linking the trans-Planckian and the information loss problems in black hole physics

The trans-Planckian and information loss problems are usually discussed in the literature as separate issues concerning the nature of Hawking radiation. Here we instead argue that they are intimately linked, and can be understood as "two sides of the same coin" once it is accepted that general relativity is an effective field theory.Comment: 10 pages, 2 figures. Replaced with the version to be published in General Relativity and Gravitatio

Magnetic Field Generation in Stars

Enormous progress has been made on observing stellar magnetism in stars from the main sequence through to compact objects. Recent data have thrown into sharper relief the vexed question of the origin of stellar magnetic fields, which remains one of the main unanswered questions in astrophysics. In this chapter we review recent work in this area of research. In particular, we look at the fossil field hypothesis which links magnetism in compact stars to magnetism in main sequence and pre-main sequence stars and we consider why its feasibility has now been questioned particularly in the context of highly magnetic white dwarfs. We also review the fossil versus dynamo debate in the context of neutron stars and the roles played by key physical processes such as buoyancy, helicity, and superfluid turbulence,in the generation and stability of neutron star fields. Independent information on the internal magnetic field of neutron stars will come from future gravitational wave detections. Thus we maybe at the dawn of a new era of exciting discoveries in compact star magnetism driven by the opening of a new, non-electromagnetic observational window. We also review recent advances in the theory and computation of magnetohydrodynamic turbulence as it applies to stellar magnetism and dynamo theory. These advances offer insight into the action of stellar dynamos as well as processes whichcontrol the diffusive magnetic flux transport in stars.Comment: 41 pages, 7 figures. Invited review chapter on on magnetic field generation in stars to appear in Space Science Reviews, Springe

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Background Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3middot2 mg/m2 every 3 weeks) received accelerated approval from the US Food and Drug Administration on the basis of efficacy in patients with small-cell lung cancer (SCLC) who relapsed after first-line platinum-based chemotherapy. The ATLANTIS trial assessed the efficacy and safety of combination lurbinectedin and the anthracycline doxorubicin as second-line treatment for SCLC.Methods In this phase 3, open-label, randomised study, adult patients aged 18 years or older with SCLC who relapsed after platinum-based chemotherapy were recruited from 135 hospitals across North America, South America, Europe, and the Middle East. Patients were randomly assigned (1:1) centrally by dynamic allocation to intravenous lurbinectedin 2middot0 mg/m2 plus doxorubicin 40middot0 mg/m2 administered on day 1 of 21-day cycles or physician's choice of control therapy (intravenous topotecan 1middot5 mg/m2 on days 1-5 of 21-day cycles; or intravenous cyclophosphamide 1000 mg/m2 , doxorubicin 45middot0 mg/m2 , and vincristine 2middot0 mg on day 1 of 21-day cycles [CAV]) administered until disease progression or unacceptable toxicity. Primary granulocyte-colony stimulating factor prophylaxis was mandatory in both treatment groups. Neither patients nor clinicians were masked to treatment allocation, but the independent review committee, which assessed outcomes, was masked to patients' treatment allocation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02566993, and with EudraCT, 2015-001641-89, and is complete.Findings Between Aug 30, 2016, and Aug 20, 2018, 613 patients were randomly assigned to lurbinectedin plus doxorubicin (n=307) or control (topotecan, n=127; CAV, n=179) and comprised the intention-to-treat population; safety endpoints were assessed in patients who had received any partial or complete study treatment infusions (lurbinectedin plus doxorubicin, n=303; control, n=289). After a median follow-up of 24middot1 months (95% CI 21middot7-26middot3), 303 patients in the lurbinectedin plus doxorubicin group and 289 patients in the control group had discontinued study treatment; progressive disease was the most common reason for discontinuation (213 [70%] patients in the lurbinectedin plus doxorubicin group vs 152 [53%] in the control group). Median overall survival was 8middot6 months (95% CI 7middot1-9middot4) in the lurbinectedin plus doxorubicin group versus 7middot6 months (6middot6-8middot2) in the control group (stratified log-rank p=0middot90; hazard ratio 0middot97 [95% CI 0middot82-1middot15], p=0middot70). 12 patients died because of treatment-related adverse events: two (<1%) of 303 in the lurbinectedin plus doxorubicin group and ten (3%) of 289 in the control group. 296 (98%) of 303 patients in the lurbinectedin plus doxorubicin group had treatment-emergent adverse events compared with 284 (98%) of 289 patients in the control group; treatment-related adverse events occurred in 268 (88%) patients in the lurbinectedin plus doxorubicin group and 266 (92%) patients in the control group.Grade 3 or worse haematological adverse events were less frequent in the lurbinectedin plus doxorubicin group than the control group (anaemia, 57 [19%] of 302 patients in the lurbinectedin plus doxorubicin group vs 110 [38%] of 288 in the control group; neutropenia, 112 [37%] vs 200 [69%]; thrombocytopenia, 42 [14%] vs 90 [31%]). The frequency of treatment-related adverse events leading to treatment discontinuation was lower in the lurbinectedin plus doxorubicin group than in the control group (26 [9%] of 303 patients in the lurbinectedin plus doxorubicin group vs 47 [16%] of 289 in the control group).Interpretation Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control.Pathogenesis and treatment of chronic pulmonary disease

Ion transport function of SLC4A11 in corneal endothelium

10.1167/iovs.13-11929Investigative Ophthalmology and Visual Science5464330-4340IOVS

SLC4A11 is an EIPA-sensitive Na+ permeable pHi regulator

10.1152/ajpcell.00056.2013American Journal of Physiology - Cell Physiology3057C716-C727AJPC